Dear Louisiana Congressional Delegation,

Our communities are struggling under rising healthcare costs, with nearly 4 in 5 Louisianans worrying about affording health care in the future. Even more concerning is the fact that 60% of Louisianans delayed or went without health care due to cost. We appreciate your leadership and efforts to ensure patient access to affordable, innovative medicines and treatments, but Louisianans are still struggling under rising healthcare costs.

As we approach the final quarter of 2025, and Congress is prioritizing what must be done before it adjourns for the year, we urge you to pass policy solutions to directly lower costs and increase access for patients. Pharmacy benefit managers (PBMs) sit at the center of this discussion. These reforms have reached the legislative finish line multiple times, only to stall due to broader political dynamics. This year, Congress must finish the job.

The six largest PBMs control 94% of all prescription drug claims and strategically create drug formularies that incentivize higher cost medications. Express Scripts, the largest PBM in Louisiana, holds 71% of the market share in our state as of 2022. These vertically integrated companies include insurance companies, PBMs, and pharmacies, and they are gaining more power, taking away decision-making from patients, physicians, and their community pharmacists. Thanks to your leadership and the work of multiple congressional committees, countless national and local media investigations, and a recent report by the Federal Trade Commission, we all now know the ways PBMs create policies that raise health care prices and harm patient access to necessary medications, while pocketing profits, without any patient benefit. As the Federal Trade Commission said in its report, PBMs "make formulary decisions to maximize profits (for

themselves [PBMs] and their health plan clients)."

Thankfully, Congress has strong bipartisan solutions at hand. We support H.R. 4317, the PBM Reform Act of 2025, introduced by Rep. Buddy Carter. The bill bans spread pricing in Medicaid, boosts transparency, delinks PBM compensation from drug prices in Medicare Part D, and strengthens CMS oversight of PBM contracts. Together with other bipartisan proposals, this legislation provides a roadmap to deliver real savings for patients, employers, and taxpayers. To be effective, PBM reform must:

- Break the link between PBM revenue and drug prices by prohibiting PBMs from profiting from higher-cost medicines.
- Mandate that all savings and rebates be passed on to patients at the point of sale.
- Streamline utilization management to ensure timely and efficient patient access to treatments.

We urge members to support H.R. 4317 by cosponsoring this important legislation.

We appreciate your leadership on this issue and strongly encourage you to prioritize action on PBM reform before adjournment. There is a broad bipartisan consensus on these reforms. There is no action Congress can take right now that would have a greater impact on making prescription drug out-of-pocket costs more affordable for American families. We strongly encourage you to seize this moment, finish the work, and deliver meaningful PBM reform this year.

Thank you,
AiArthritis
Al Copeland Foundation
American Senior Alliance
Biomarker Collaborative
Cancer Advocacy Group of Louisiana
Coalition of Hematology and Oncology Practices
Coalition of State Rheumatology Organizations
Community Access National Network in Slidell
Epilepsy Alliance Louisiana
Exon 20 Group
Gaucher Community Alliance
HEALS of the South
Hispanic Chamber of Commerce of Louisiana
Infusion Access Foundation
International Cancer Advocacy Network
Louisiana Mental Health Association
Louisiana Oncology Society
Lupus and Allied Diseases
Mauti Cancer Fund
MET Crusaders
Multiple Sclerosis Foundation
National Infusion Center Association
National Kidney Foundation of Louisiana
Neuropathy Action Foundation
PD-L1 Amplifieds
Pontchartrain Cancer Center
Rheumatology Alliance of Louisiana
Survivors Cancer Action Network